Zeiss Unveils New Ion Beam Microscope Capabilities
The updated microscopes will cover a wider range of tasks across analytics, tomography, sample preparation, and data integrity.
Zeiss, an optics and optoelectronics technology enterprise company, introduced additional functions for its Zeiss ion beam microscopes, making the devices capable of handling engineering materials, energy materials, soft materials, geosciences covering megatrends in additive manufacturing, etc. for analytics, tomography, sample preparation, and data integrity.
The microscopes will be equipped with secondary ion mass spectrometry solutions for elemental analysis and time-of-flight secondary ion mass spectrometry detection for analytical purposes. Along with this, the tomography functions of the microscopes will be enhanced by workflows for 3D tomography to ensure quality 3D data volume generation with quantified and calibrated measurement of z-slice thickness for reconstruction of tomogram slices into a reconstructed volume.
A new loading station and sample holder for transmission electron microscopy (TEM) lamella preparation leads to an easier transition of the sample to the TEM for further analysis. Data integrity is also enhanced with ZEISS ZEN Intellesis, a machine learning-based segmentation software that ensures data integrity is maintained as data acquisition speed and quality are improved.
Source: Zeiss
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
